J&J Sees New MOAs For Refractory Populations As Anti-Depressant For Neuro Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J’s five key therapeutic areas appear to be operating on all cylinders, based on presentations at the company’s annual analyst meeting. In neuroscience, already one of its core fields, it is expanding its anti-psychotic and mood disorders franchise to focus on difficult-to-treat patients, as well re-doubling efforts in challenging diseases like Alzheimer’s disease.